Proteomic approaches in lung cancer biomarker development

References

• Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer75(1 Suppl.), 191–202 (1995).
   PubMed Web of Science ®Google Scholar
• Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest132(1), 185–192 (2007).
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol.25(5), 561–570 (2007).
   PubMed Web of Science ®Google Scholar
• Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am. Fam. Physician75(1), 56–63 (2007).
   PubMed Web of Science ®Google Scholar
• Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am. J. Respir. Cell Mol. Biol.32(3), 169–176 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison TR, Fauci AS. Harrison’s Principles of Internal Medicine. McGraw-Hill, Health Professions Division, NY, USA (1998).
   Google Scholar
• Midthun DE, Jett JR. Update on screening for lung cancer. Semin. Respir. Crit. Care Med.29(3), 233–240 (2008).
   PubMed Web of Science ®Google Scholar
• Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest111(6), 1710–1717 (1997).
   PubMed Web of Science ®Google Scholar
• Dalton WS, Friend SH. Cancer biomarkers – an invitation to the table. Science312(5777), 1165–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr. Opin. Mol. Ther.2(6), 643–650 (2000).
   PubMed Web of Science ®Google Scholar
• Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep.41(9), 615–625 (2008).
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin. Pharmacother.4(6), 963–971 (2003).
   PubMed Web of Science ®Google Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol.10(6), 548–551 (1998).
   PubMedGoogle Scholar
• Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol.29(3 Suppl. 11), 4–10 (2002).
   PubMedGoogle Scholar
• Brambilla C, Fievet F, Jeanmart M et al. Early detection of lung cancer: role of biomarkers. Eur. Respir. J.39, S36–S44 (2003).
   Google Scholar
• Bartlett JM, Stirling D. A short history of the polymerase chain reaction. Methods Mol. Biol.226, 3–6 (2003).
   PubMedGoogle Scholar
• Valle RP, Chavany C, Zhukov TA, Jendoubi M. New approaches for biomarker discovery in lung cancer. Expert Rev. Mol. Diagn.3(1), 55–67 (2003).
   PubMed Web of Science ®Google Scholar
• Tockman MS. Clinical detection of lung cancer progression markers. J. Cell. Biochem.25, 177–184 (1996).
   Google Scholar
• Shoemaker DD, Schadt EE, Armour CD et al. Experimental annotation of the human genome using microarray technology. Nature409(6822), 922–927 (2001).
   PubMed Web of Science ®Google Scholar
• Young GD, Winokur TS, Cerfolio RJ et al. Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes. Lung Cancer36(2), 133–141 (2002).
   PubMedGoogle Scholar
• Hoehn GT, Suffredini AF. Proteomics. Crit. Care Med.33(12 Suppl.), S444–S448 (2005).
   PubMed Web of Science ®Google Scholar
• Wisniewski JR. Mass spectrometry-based proteomics: principles, perspectives, and challenges. Arch. Pathol. Lab. Med.132(10), 1566–1569 (2008).
   Google Scholar
• Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotech.16(9), 373–378 (1998).
   PubMed Web of Science ®Google Scholar
• Kell DB. Metabolomic biomarkers: search, discovery and validation. Expert Rev. Mol. Diagn.7(4), 329–333 (2007).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology12(1), 22–28 (2007).
   PubMed Web of Science ®Google Scholar
• Chen G, Gharib TG, Wang H et al. Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl Acad. Sci. USA100(23), 13537–13542 (2003).
   PubMed Web of Science ®Google Scholar
• Okano T, Kondo T, Fujii K et al. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin. Cancer Res.13(3), 799–805 (2007).
   PubMed Web of Science ®Google Scholar
• Xiao T, Ying W, Li L et al. An approach to studying lung cancer-related proteins in human blood. Mol. Cell. Proteomics4(10), 1480–1486 (2005).
   PubMed Web of Science ®Google Scholar
• Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl Acad. Sci. USA76(9), 4350–4354 (1979).
   PubMed Web of Science ®Google Scholar
• Gadkari DA, Shaikh BH. IgM antibody capture ELISA in the diagnosis of Japanese encephalitis, West Nile & dengue virus infections. Indian J. Med. Res.80, 613–619 (1984).
   Google Scholar
• Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin. Chem.51(12), 2415–2418 (2005).
   PubMed Web of Science ®Google Scholar
• Torane VP, Shastri JS. Comparison of ELISA and rapid screening tests for the diagnosis of HIV, Hepatitis B and Hepatitis C among healthy blood donors in a tertiary care hospital in Mumbai. Indian J. Med. Microbiol.26(3), 284–285 (2008).
   Google Scholar
• Paltiel AD, Weinstein MC, Kimmel AD et al. Expanded screening for HIV in the United States – an analysis of cost-effectiveness. N. Engl. J. Med.352(6), 586–595 (2005).
   PubMed Web of Science ®Google Scholar
• Donati V, Faviana P, Dell’omodarme M et al. Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer. Hum. Pathol.35(11), 1347–1352 (2004).
   PubMed Web of Science ®Google Scholar
• Tan D, Deeb G, Wang J et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol.12(4), 201–211 (2003).
   PubMed Web of Science ®Google Scholar
• Gao WM, Kuick R, Orchekowski RP et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer5, 110 (2005).
   PubMedGoogle Scholar
• Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am. J. Respir. Crit. Care Med.172(10), 1308–1314 (2005).
   PubMed Web of Science ®Google Scholar
• Amann JM, Chaurand P, Gonzalez A et al. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin. Cancer Res.12(17), 5142–5150 (2006).
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Shyr Y, Xu BJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet362(9382), 433–439 (2003).
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• Chen EI, Hewel J, Felding-Habermann B, Yates JR 3rd. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol. Cell. Proteomics5(1), 53–56 (2006).
   PubMed Web of Science ®Google Scholar
• Jessani N, Niessen S, Wei BQ et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods2(9), 691–697 (2005).
   PubMedGoogle Scholar
• Tyan YC, Wu HY, Lai WW, Su WC, Liao PC. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J. Proteome Res.4(4), 1274–1286 (2005).
   Google Scholar
• Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol.4, 222 (2008).
   PubMed Web of Science ®Google Scholar
• Luna LG, Williams TL, Pirkle JL, Barr JR. Ultra performance liquid chromatography isotope dilution tandem mass spectrometry for the absolute quantification of proteins and peptides. Anal. Chem.80(8), 2688–2693 (2008).
   Google Scholar
• Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics5(4), 573–588 (2006).
   PubMed Web of Science ®Google Scholar
• Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics6(12), 2212–2229 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res.3(2), 235–244 (2004).
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Bernhard OK, Greening DW, Moritz RL. Proteomics-driven cancer biomarker discovery: looking to the future. Curr. Opin. Chem. Biol.12(1), 72–77 (2008).
   PubMed Web of Science ®Google Scholar
• Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr. Opin. Pulm. Med.13(4), 249–255 (2007).
   PubMed Web of Science ®Google Scholar
• Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer8(1), 30–38 (2006).
   PubMed Web of Science ®Google Scholar
• Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res.52(10), 2903–2906 (1992).
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res.52(9 Suppl.), S2665–S2669 (1992).
   PubMed Web of Science ®Google Scholar
• Niklinski J, Niklinska W, Chyczewski L, Becker HD, Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur. J. Cancer Prev.10(3), 213–226 (2001).
   PubMedGoogle Scholar
• Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J. Clin. Oncol.16(3), 1207–1217 (1998).
   PubMed Web of Science ®Google Scholar
• Gazzeri S, Brambilla E, Caron de Fromentel C et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer58(1), 24–32 (1994).
   PubMedGoogle Scholar
• Brambilla E, Gazzeri S, Lantuejoul S et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin. Cancer Res.4(7), 1609–1618 (1998).
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell88(3), 323–331 (1997).
   PubMed Web of Science ®Google Scholar
• Kerr KM, Carey FA, King G, Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J. Pathol.174(4), 249–256 (1994).
   PubMedGoogle Scholar
• Westra WH, Baas IO, Hruban RH et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res.56(9), 2224–2228 (1996).
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Shimizu E, Sumitomo K et al. L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and pleural effusion from a patient with non-small cell lung cancer. Intern. Med.36(10), 724–727 (1997).
   PubMed Web of Science ®Google Scholar
• Hida T, Ogawa S, Park JC et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther.,9(1), 17–35 (2009).
   PubMed Web of Science ®Google Scholar
• Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics7(23), 4292–4302 (2007).
   PubMed Web of Science ®Google Scholar
• Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer40(3), 267–279 (2003).
   PubMed Web of Science ®Google Scholar
• Kulpa J, Wójcik E, Radkowski A, Kolodziejski L, Stasik Z.CYFRA 21–1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res.20(6D), 5035–5040 (2000).
   Google Scholar
• Molina R, Auge JM, Filella X et al. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21–1 and NSE in patients with lung cancer. Anticancer Res.25(3A), 1773–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Auge JM et al. Tumor markers (CEA, CA 125, CYFRA 21–1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol.24(4), 209–218 (2003).
   PubMed Web of Science ®Google Scholar
• Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest124(2), 622–632 (2003).
   PubMed Web of Science ®Google Scholar
• Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21–1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res.23(2A), 885–893 (2003).
   PubMed Web of Science ®Google Scholar
• Hampton R, Walker M, Marshall J, Juhl H. Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene21(51), 7817–7823 (2002).
   PubMedGoogle Scholar
• Trauner M, Grygar S, Stauber RE, Brodatsch-Hausler E, Klimpfinger M. Carcinoembryonic antigen, cytokeratin expression and mucin composition in hyperplastic and neoplastic polyps of the colorectum. Z. Gastroenterol.32(11), 626–631 (1994).
   Google Scholar
• Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Hematol. Oncol. Clin. North Am.11(3), 409–434 (1997).
   PubMedGoogle Scholar
• Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem.37(7), 529–540 (2004).
   PubMed Web of Science ®Google Scholar
• Lamy P, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer29(3), 197–203 (2000).
   Google Scholar
• Shibayama T, Ueoka H, Nishii K et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer32(1), 61–69 (2001).
   PubMed Web of Science ®Google Scholar
• Maciel CM, Junqueira M, Paschoal ME et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J. Exp. Ther. Oncol.5(1), 31–38 (2005).
   PubMedGoogle Scholar
• Chi-Shing Cho W. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmacother.61(9), 515–519 (2007).
   PubMed Web of Science ®Google Scholar
• Dowling P, O’Driscoll L, Meleady P et al. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis28(23), 4302–4310 (2007).
   PubMed Web of Science ®Google Scholar
• Grossi F, Loprevite M, Chiaramondia M et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur. J. Cancer39(9), 1242–1250 (2003).
   PubMed Web of Science ®Google Scholar
• Mizera-Nyczak E, Dyszkiewicz W, Heider KH, Zeromski J. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol.22(1), 45–53 (2001).
   Google Scholar
• Okada M, Nishio W, Sakamoto T et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann. Thorac. Surg.78(1), 216–221 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider J. Tumor markers in detection of lung cancer. Adv. Clin. Chem.42, 1–41 (2006).
   PubMed Web of Science ®Google Scholar
• Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21–1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem.48(11), 1931–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res.21(2B), 1241–1246 (2001).
   PubMed Web of Science ®Google Scholar
• Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin. Biochem.37(7), 505–511 (2004).
   PubMed Web of Science ®Google Scholar
• Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer39(2), 131–138 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer41(3), 311–320 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou J, Nong L, Wloch M, Cantor A, Mulshine JL, Tockman MS. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer34(3), 341–350 (2001).
   PubMedGoogle Scholar
• Meert AP, Martin B, Verdebout JM et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer44(3), 295–301 (2004).
   Google Scholar
• Filiberti R, Marroni P, Paganuzzi M et al. c-erbB-2 protein in serum of primary lung cancer patients. Cancer Detect. Prev.26(1), 64–68 (2002).
   Google Scholar
• Garg S, Handa U, Mohan H, Janmeja AK. Comparative analysis of various cytohistological techniques in diagnosis of lung diseases. Diagn. Cytopathol.35(1), 26–31 (2007).
   PubMed Web of Science ®Google Scholar
• Xing S, Khanavkar B, Nakhosteen JA, Atay Z, Jockel KH, Marek W. Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers. Eur. Respir. J.25(6), 956–963 (2005).
   Google Scholar
• Gazdar AF, Minna JD. Molecular detection of early lung cancer. J. Natl Cancer Inst.91(4), 299–301 (1999).
   PubMedGoogle Scholar
• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature452(7187), 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics5(13), 3292–3303 (2005).
   PubMed Web of Science ®Google Scholar
• Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer95(9), 1886–1893 (2002).
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8), 971–983 (2006).
   PubMed Web of Science ®Google Scholar